Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, Séverine Vermeire, Tomáš Vaňásek et al.|Journal of Crohn s and Colitis|2021Cited by 34
772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT IISilvio Danese, Séverine Vermeire, William J. Sandborn et al.|The American Journal of Gastroenterology|2019Cited by 1
P081 Rapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT IISilvio Danese, Séverine Vermeire, William J. Sandborn et al.|The American Journal of Gastroenterology|2019Cited by 0